First study niraparib
WebMar 23, 2024 · The phase III MAGNITUDE study was designed to compare the efficacy and safety of niraparib + AAP versus placebo + AAP for first-line mCRPC. Clinical data have shown the efficacy of combining androgen receptor–targeted therapy and a PARP inhibitor in metastatic prostate cancer, but the patient population who could have an optimal … WebAug 7, 2024 · The results of the study formed the evidence basis for approval of niraparib as the only oral, once-daily PARPi as monotherapy maintenance treatment for women with first-line platinum-responsive advanced ovarian cancer, regardless of biomarker status, in both the USA and EU, and more recently the United Kingdom (Fig. 4).
First study niraparib
Did you know?
WebApr 14, 2024 · A study of ovarian cancers found that the loss of TP53, a tumour suppressor gene which has direct and indirect roles within the DDR ... assessed the safety and efficacy of combination niraparib and bevacizumab as first-line maintenance for newly diagnosed advanced-stage ovarian cancer. Analysis at 28.7 months found a median PFS of 28.3 … WebNiraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP), has been associated with significantly increased progression-free survival
WebNiraparib is marketed in the United States and Europe under the trade name Zejula ®. About PRIMA. PRIMA is a double-blind, randomised Phase 3 study designed to evaluate niraparib versus placebo in first-line Stage III or IV ovarian cancer patients. WebJul 2, 2024 · Study Description Go to Brief Summary: This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described …
WebApr 11, 2024 · At the beginning of the study period, due to economic reasons, niraparib was often reserved as a last resort when patients were resistant or intolerable to … WebApr 11, 2024 · Of the total 142 patients, 93 received niraparib as first-line maintenance therapy, 31 as maintenance therapy for platinum-sensitive recurrent ovarian cancer, and 18 as salvage treatment. ... The study was conducted in accordance with the ethical standards of the Declaration of Helsinki, and the ethics committee of the main study center Fudan ...
WebSep 3, 2024 · The primary strength of this study is that it represents one of the first investigations of a PARP inhibitor with a PD-1 inhibitor for the first-line treatment of NSCLC. Niraparib in combination with pembrolizumab …
WebMay 26, 2024 · Niraparib (ZEJULA) is the first selective poly (ADP-ribose) polymerase inhibitor (PARPi) approved in the US and Europe for maintenance treatment in pts with recurrent OC regardless of BRCA mut status. Preclinical data suggest synergy with … flag of khersonWebApr 29, 2024 · On April 29, 2024, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal … canon burghardtWebNov 30, 2024 · A study of niraparib combined with MGD013 in patients with advanced or metastatic solid tumor who failed prior treatment. clinicaltrials.gov. Updated April 1, 2024. Accessed November 30, 2024 ... canonbury orthoticsWebFeb 28, 2024 · The NDA is supported by data from the MAGNITUDE study (NCT03748641), a Phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of niraparib plus AAP as a first-line treatment in patients with mCRPC, with or without alterations in HRR associated genes. [1] canon bridge kamera 100 fach optischer zoomWebMar 22, 2024 · The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the Society of Gynecologic Oncology (SGO) 2024 Virtual … canonbury kitchen reviewWebFeb 17, 2024 · Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology … flag of khivaWebOct 8, 2024 · Niraparib is the first oral PARPi approved for maintenance in patients with recurrent ovarian cancer, regardless of BRCA mutation status; in the NOVA study, it … canonbury kitchen islington